バイエルのインスタグラム(bayerofficial) - 2月17日 20時43分

Research focus - Hemophilia ❤️?? Bayer has a long history of research and development in the area of hemophilia. Hemophilia is a genetic defect and is inherited recessively on the X chromosome, so it primarily affects men. These patients lack a protein that among others causes the blood to clot as part of the natural wound-healing process. In hemophilia A, which affects 80-85 percent of patients with hemophilia, it is the blood clotting factor VIII that is lacking. Severe hemophilia is characterized by spontaneous bleeding into joints, muscles and various organs, even if there are no external injuries. This bleeding can lead to permanent disability or even death at any age.
Modern therapies enable patients to lead a virtually normal, active life: the missing clotting factor is replaced by a 'recombinant factor', which is manufactured using genetically modified mammalian cells. When administered intravenously, the recombinant factor helps to stop acute bleeding at an early stage or may prevent it altogether by regular prophylaxis. The recombinant factor VIII developed by Bayer for treating hemophilia A was one of the first products of its kind. It was launched in 1993.
#research #medicine #science #education #meds #medic #medical #doctor #lifescience #betterlife #chemistry #biology #scientist #makeportraits #agameoftones #artofvisuals #makemoments #visualsoflife #justgoshoot #liveauthentic #thecreatorclass #peoplescreatives #letsgosomewhere #everydayeverywhere #illgrammers #chasinglight #createxplore

[BIHAKUEN]UVシールド(UVShield)

>> 飲む日焼け止め！「UVシールド」を購入する